Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Respir Med. 2016 Mar 21;114:53–60. doi: 10.1016/j.rmed.2016.03.012

Table 5.

Outcomes in patients with HP

Characteristics HPAF
(n=18)		 HP without AF
(n=102)		 p-value
Deceased, n (%) 5 (27.8) 24 (23.5) 0.698
 Mean survival period, months (±SD) 16.5 (13.0) 29.7 (21.5) 0.103
Transplanted, n (%) 1 (5.6) 4 (3.9) 0.749
 Mean Time to transplant, months (±SD) 23.6 (0) 33.2 (28.4) 0.528
10% FVC decline*, n (%) 6 (50) 24 (30.4) 0.178
 Mean Time to 10% FVC decline, months (±SD) 26.2 (16) 18.2 (18.2) 0.337

HP = Hypersensitivity Pneumonitis; HPAF= Hypersensitivity Pneumonitis with Autoimmune features as defined in the text; AF = Autoimmune features

*

Follow up FVC available for 91 HP patients; 12 and 79, with and without autoimmune disease or features respectively.